Summary
Danaher Corporation (DHR) reported a strong financial performance for the fiscal year ended December 30, 2021, driven by significant growth across its key segments, particularly Life Sciences and Diagnostics. The company achieved substantial revenue growth, aided by strategic acquisitions, including the significant acquisition of Aldevron. Danaher's robust financial position is underscored by increased operating profit margins and healthy cash flow from operations, demonstrating effective execution of its Danaher Business System (DBS) and strategic priorities. Despite potential headwinds from supply chain disruptions and global economic uncertainties, Danaher's diversified business model and focus on innovation in science and technology markets have allowed it to navigate these challenges effectively. The company's commitment to attracting and retaining talent, coupled with ongoing investments in research and development, positions it for continued growth and value creation for shareholders. Investors can look forward to Danaher's continued focus on portfolio enhancement through strategic capital allocation and operational excellence.
Financial Highlights
52 data points| Revenue | $24.80B |
| Cost of Revenue | $9.56B |
| Gross Profit | $15.24B |
| R&D Expenses | $1.50B |
| SG&A Expenses | $6.82B |
| Operating Income | $6.38B |
| Interest Expense | $231.00M |
| Net Income | $6.43B |
| EPS (Basic) | $8.77 |
| EPS (Diluted) | $8.61 |
| Shares Outstanding (Basic) | 714.60M |
| Shares Outstanding (Diluted) | 736.80M |
Key Highlights
- 1Danaher reported strong overall sales growth of 32.0% for the year ended December 31, 2021, compared to the prior year.
- 2The Life Sciences segment saw a significant 41.5% increase in sales, driven by strong demand in bioprocessing and genomics, including contributions from the Cytiva and Aldevron acquisitions.
- 3The Diagnostics segment also experienced robust growth with a 33.0% increase in sales, primarily due to demand for molecular diagnostics and core lab products, including COVID-19 testing solutions.
- 4Operating profit margins improved significantly to 25.3% in 2021 from 19.0% in 2020, reflecting increased sales volumes and productivity improvements.
- 5The company acquired Aldevron for approximately $9.6 billion, expanding its Life Sciences segment's capabilities in genomic medicine.
- 6Danaher generated substantial operating cash flow from continuing operations of $8.4 billion in 2021, a 34% increase year-over-year.
- 7The company ended the year with a strong liquidity position, holding $2.6 billion in cash and cash equivalents.